Passage BIO, Inc. Quick Ratio
The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.
- Passage BIO, Inc. quick ratio for the quarter ending 2026-06-30 was 1.17, a 59.94% decline year-over-year.
- Passage BIO, Inc. quick ratio for the quarter ending 2026-03-31 was 1.66, a 53.35% decline year-over-year.
- Passage BIO, Inc. quick ratio for the quarter ending 2025-12-31 was 2.01, a 3.37% increase year-over-year.
- Passage BIO, Inc. quick ratio for the quarter ending 2025-09-30 was 2.37, a 24.53% increase year-over-year.
- Passage BIO, Inc. quick ratio for fiscal 2025 was 2.01, a 3.37% increase from fiscal 2024.
- Passage BIO, Inc. quick ratio for fiscal 2024 was 1.94, a 46.06% increase from fiscal 2023.
- Passage BIO, Inc. quick ratio for fiscal 2023 was 1.33, a 29.54% decline from fiscal 2022.
- Passage BIO, Inc. quick ratio for fiscal 2022 was 1.89, a 56.87% decline from fiscal 2021.
- Available history
- 2019-12-31 to 2026-06-30
- Data captured
Historical Quick Ratio
Annual Quick Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |